ArticleMetabolic brain disease2026
Isoniazid impairs memory function in male Swiss mice by elevating pro-inflammatory cytokines and disruption of hippocampal, and prefrontal cortex neuronal morphology.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isoniazid (INH), a first-line antibiotic for tuberculosis treatment, is known for its efficacy but also for its potential to cause neurotoxic side effects, which include peripheral neuropathy, seizures, and in rare cases, psychosis. This study aimed to evaluate the neurotoxic effects of INH on memory function and its underlying mechanisms in male Swiss mice. Eighteen male Swiss mice (n = 6 per group) were treated orally with INH at doses of 5, 10, and 20 mg/kg for 28 days. The behavioral tests for memory using Y-maze and Morris water maze were conducted afterwards. The brain tissues of the animals were processed for determination of oxidative stress/antioxidant markers, pro-inflammatory cytokines, and neurotransmitter enzymes (acetylcholinesterase and glutamate decarboxylase).The histomorphology of the hippocampus and prefrontal cortex regions of the brains of the animals was done using the Hematoxylin and Eosin staining techniques. The results of the study showed that INH produced a reduction in memory function, with significant impairments at higher doses in the Morris water maze test. Biochemical analyses revealed increased lipid peroxidative product, reduced antioxidant defenses, and elevated pro-inflammatory cytokines in the hippocampus and prefrontal cortex of mice treated with INH. It also produced neurotransmitter enzymes dysregulations of the discrete brain regions of mice treated with INH. The histomorphorological studies revealed that INH produced structural changes in the hippocampus and prefrontal cortex and marked loss of viable neuronal cells. The results obtained from these studies suggest that INH treatment causes memory impairment. These findings highlight the need for strategies to minimize cognitive side effects in patients with tuberculosis on INH therapy.
Indexed as
Identifiers
42704558What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.